Top

Published in:

01-01-2012 | Original Contribution

Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy

Published in: Basic Research in Cardiology | Issue 1/2012

Abstract

Several lines of evidence suggest that alterations of the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP) may be involved in cardiac diseases. Little is known, however, in hypertrophic cardiomyopathy (HCM). This study studied these pathways in two mouse models of HCM that mainly differ by the presence or absence of truncated mutant proteins. Analyses were performed in homozygous Mybpc3-targeted knock-in (KI) mice, carrying a HCM mutation and exhibiting low levels of mutant cardiac myosin-binding protein C (cMyBP-C), and in Mybpc3-targeted knock-out (KO) mice expressing no cMyBP-C, thus serving as a model of pure cMyBP-C insufficiency. In the early postnatal development of cardiac hypertrophy, both models showed higher levels of ubiquitinated proteins and greater proteasomal activities. To specifically monitor the degradation capacity of the UPS with age, mice were crossed with transgenic mice that overexpress Ub^G76V-GFP. Ub^G76V-GFP protein levels were fourfold higher in 1-year-old KI, but not KO mice, suggesting a specific UPS impairment in mice expressing truncated cMyBP-C. Whereas protein levels of key ALP markers were higher, suggesting ALP activation in both mutant mice, their mRNA levels did not differ between the groups, underlying rather defective ALP-mediated degradation. Analysis of key proteins regulated in heart failure did not reveal specific alterations in KI and KO mice. Our data suggest (1) UPS activation in early postnatal development of cardiac hypertrophy, (2) specific UPS impairment in old KI mice carrying a HCM mutation, and (3) defective ALP as a common mechanism in genetically engineered mice with cardiac hypertrophy.

Available only for authorised users

Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto Y, Shirayoshi Y, Kitakaze M, Carrier L, Hisatome I (2008) Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol 384:896–907. doi:10.1016/j.jmb.2008.09.070 PubMedCrossRef

Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD, Cooper IV G, Tuxworth WJ, Kuppuswamy D (2006) Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 41:669–679 doi:10.1016/j.yjmcc.2006.04.022

Bardswell SC, Cuello F, Rowland AJ, Sadayappan S, Robbins J, Gautel M, Walker JW, Kentish JC, Avkiran M (2010) Distinct sarcomeric substrates are responsible for protein kinase D-mediated regulation of cardiac myofilament Ca²⁺ sensitivity and cross-bridge cycling. J Biol Chem 285:5674–5682. doi:10.1074/jbc.M109.066456 PubMedCrossRef

Birks EJ, Latif N, Enesa K, Folkvang T, le Luong A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC (2008) Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79:472–480. doi:10.1093/cvr/cvn083 PubMedCrossRef

Breitschopf K, Zeiher AM, Dimmeler S (2000) Ubiquitin-mediated degradation of the proapoptotic active form of bid: a functional consequence on apoptosis induction. J Biol Chem 275:21648–21652. doi:10.1074/jbc.M001083200 PubMedCrossRef

Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, Hainque B, Cruaud C, Gary F, Labeit S, Bouhour JB, Dubourg O, Desnos M, Hagege AA, Trent RJ, Komajda M, Fiszman M, Schwartz K (1997) Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res 80:427–434PubMed

Carrier L, Knoell R, Vignier N, Keller DI, Bausero P, Prudhon B, Isnard R, Ambroisine ML, Fiszman M, Ross J Jr, Schwartz K, Chien KR (2004) Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 63:293–304. doi:10.1016/j.cardiores.2004.04.009 PubMedCrossRef

Carrier L, Schlossarek S, Willis MS, Eschenhagen T (2010) The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res 85:330–338. doi:10.1093/cvr/cvp247 PubMedCrossRef

Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J, Li F, Gerdes AM, Wawrousek EF, Wang X (2005) Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 97:1018–1026. doi:10.1161/01.RES.0000189262.92896.0b PubMedCrossRef

10.

Cuello F, Bardswell SC, Haworth RS, Ehler E, Sadayappan S, Kentish JC, Avkiran M (2011) Novel role for p90 ribosomal S6 kinase in the regulation of cardiac myofilament phosphorylation. J Biol Chem 286:5300–5310. doi:10.1074/jbc.M110.202713 PubMedCrossRef

11.

Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 18:538–543. doi:10.1038/75406 PubMedCrossRef

12.

De Meyer GR, Martinet W (2009) Autophagy in the cardiovascular system. Biochim Biophys Acta 1793:1485–1495. doi:10.1016/j.bbamcr.2008.12.011 PubMedCrossRef

13.

Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821–1828. doi:10.1161/CIRCULATIONAHA.106.637827 PubMedCrossRef

14.

Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, Ron D, Yin XM (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171:513–524. doi:10.2353/ajpath.2007.070188 PubMedCrossRef

15.

El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T, Carrier L (2007) Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 43:223–229. doi:10.1016/j.yjmcc.2007.05.003 PubMedCrossRef

16.

Flavigny J, Souchet M, Sebillon P, Berrebi-Bertrand I, Hainque B, Mallet A, Bril A, Schwartz K, Carrier L (1999) COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. J Mol Biol 294:443–456. doi:10.1006/jmbi.1999.3276S0022-2836(99)93276-X PubMedCrossRef

17.

Gautel M, Zuffardi O, Freiburg A, Labeit S (1995) Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J 14:1952–1960PubMed

18.

Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428. doi:10.1152/physrev.00027.2001 PubMed

19.

Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X, Madura K, Depre C (2008) Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res 77:497–505. doi:10.1093/cvr/cvm054 PubMedCrossRef

20.

Helin K (1998) Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 8:28–35. doi:10.1016/S0959-437X(98)80058-0 PubMedCrossRef

21.

King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652–1659PubMedCrossRef

22.

Kirkin V, Dikic I (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol 19:199–205. doi:10.1016/j.ceb.2007.02.002 PubMedCrossRef

23.

Kirkin V, McEwan DG, Novak I, Dikic I (2009) A role for ubiquitin in selective autophagy. Mol Cell 34:259–269. doi:10.1016/j.molcel.2009.04.026 PubMedCrossRef

24.

Kooij V, Boontje N, Zaremba R, Jaquet K, dos Remedios C, Stienen GJ, van der Velden J (2010) Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca²⁺ sensitivity in human myocardium. Basic Res Cardiol 105:289–300. doi:10.1007/s00395-009-0053-z PubMedCrossRef

25.

Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovekorn WP, Schaper J (2003) Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92:715–724. doi:10.1161/01.RES.0000067471.95890.5C PubMedCrossRef

26.

Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132:27–42. doi:10.1016/j.cell.2007.12.018 PubMedCrossRef

27.

Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850–3855. doi:10.1073/pnas.070047997 PubMedCrossRef

28.

Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114:1058–1071PubMed

29.

Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X (2011) Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest 121:3689–3700. doi:10.1172/JCI45709 PubMedCrossRef

30.

Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP (2003) A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 21:897–902PubMedCrossRef

31.

Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H (2009) Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 105:219–222. doi:10.1161/CIRCRESAHA.109.202440 PubMedCrossRef

32.

McClellan G, Kulikovskaya I, Winegrad S (2001) Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys J 81:1083–1092PubMedCrossRef

33.

Mearini G, Gedicke C, Schlossarek S, Witt CC, Kramer E, Cao P, Gomes MD, Lecker SH, Labeit S, Willis MS, Eschenhagen T, Carrier L (2010) Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res 85:357–366. doi:10.1093/cvr/cvp348 PubMedCrossRef

34.

Mearini G, Schlossarek S, Willis MS, Carrier L (2008) The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 1782:749–763. doi:10.1016/j.bbadis.2008.06.009 PubMed

35.

Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008) Autophagy fights disease through cellular self-digestion. Nature 451:1069–1075. doi:10.1038/nature06639 PubMedCrossRef

36.

Moolman JA, Reith S, Uhl K, Bailey S, Gautel M, Jeschke B, Fischer C, Ochs J, McKenna WJ, Klues H, Vosberg HP (2000) A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 101:1396–1402PubMed

37.

Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773–785 pii:S0092-8674(94)90482-0PubMedCrossRef

38.

Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Overvatn A, Bjorkoy G, Johansen T (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282:24131–24145. doi:10.1074/jbc.M702824200 PubMedCrossRef

39.

Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR, Day SM (2010) Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121:997–1004. doi:10.1161/CIRCULATIONAHA.109.904557 PubMedCrossRef

40.

Razeghi P, Baskin KK, Sharma S, Young ME, Stepkowski S, Essop MF, Taegtmeyer H (2006) Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun 342:361–364. doi:10.1016/j.bbrc.2006.01.163 PubMedCrossRef

41.

Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M (2003) Hypertrophic Cardiomyopathy: Distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 107:2227–2232. doi:10.1161/01.CIR.0000066323.15244.54 PubMedCrossRef

42.

Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761–771 pii:S0092-8674(94)90462-6PubMedCrossRef

43.

Rottbauer W, Gautel M, Zehelein J, Labeit S, Franz WM, Fischer C, Vollrath B, Mall G, Dietz R, Kubler W, Katus HA (1997) Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy: characterization of cardiac transcript and protein. J Clin Invest 100:475–482. doi:10.1172/JCI119555 PubMedCrossRef

44.

Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T, Zolk O (2005) Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 66:33–44. doi:10.1016/j.cardiores.2005.12.021 PubMedCrossRef

45.

Schlossarek S, Carrier L (2011) The ubiquitin-proteasome system in cardiomyopathies. Curr Opin Cardiol 26:190–195. doi:10.1097/HCO.0b013e32834598fe PubMedCrossRef

46.

Schlossarek S, Mearini G, Carrier L (2011) Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J Mol Cell Cardiol 50:613–620. doi:10.1016/j.yjmcc.2011.01.014 PubMedCrossRef

47.

Schlossarek S, Schuermann F, Mearini G, Geertz B, Eschenhagen T, Carrier L (2012) Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice. J Muscle Res Cell Motil doi:10.1007/s10974-011-9273-6 (in press)

48.

Su H, Wang X (2010) The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res 85:253–262. doi:10.1093/cvr/cvp287 PubMedCrossRef

49.

Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14:2201–2214. doi:10.1089/ars.2010.3482 PubMedCrossRef

50.

Tannous P, Zhu H, Nemchenko A, Berry JM, Johnstone JL, Shelton JM, Miller FJ Jr, Rothermel BA, Hill JA (2008) Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. Circulation 117:3070–3078. doi:10.1161/CIRCULATIONAHA.107.763870 PubMedCrossRef

51.

Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H, Liao Y, Okazaki H, Asai M, Hirata A, Fujita M, Asano Y, Yamazaki S, Asanuma H, Hori M, Kitakaze M (2006) Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 340:1125–1133 doi:10.1016/j.bbrc.2005.12.120

52.

van Dijk SJ, Dooijes D, Dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, Ten Cate FJ, Stienen GJ, van der Velden J (2009) Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119:1473–1483. doi:10.1161/CIRCULATIONAHA.108.838672 PubMedCrossRef

53.

Vignier N, Schlossarek S, Fraysse B, Mearini G, Kramer E, Pointu H, Mougenot N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 105:239–248. doi:10.1161/CIRCRESAHA.109.201251 PubMedCrossRef

54.

Voigt A, Bartel K, Egerer K, Trimpert C, Feist E, Gericke C, Kandolf R, Klingel K, Kuckelkorn U, Stangl K, Felix SB, Baumann G, Kloetzel PM, Staudt A (2010) Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy. Basic Res Cardiol 105:9–18. doi:10.1007/s00395-009-0061-z PubMedCrossRef

55.

Voigt A, Trimpert C, Bartel K, Egerer K, Kuckelkorn U, Feist E, Gericke C, Klingel K, Kandolf R, Felix SB, Baumann G, Kloetzel PM, Stangl K, Staudt A (2010) Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy. Basic Res Cardiol 105:557–567. doi:10.1007/s00395-010-0096-1 PubMedCrossRef

56.

Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ (2003) Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3:208–216. doi:10.1002/(SICI)1522-2683(19990101)20:4/5<898:AID-ELPS898>3.0.CO;2-B PubMedCrossRef

57.

Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J (1999) In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res 85:841–847PubMed

58.

Zheng Q, Li J, Wang X (2009) Interplay between the ubiquitin-proteasome system and autophagy in proteinopathies. Int J Physiol Pathophysiol Pharmacol 1:127–142PubMed

59.

Zheng Q, Wang X (2010) Autophagy and the ubiquitin-proteasome system in cardiac dysfunction. Panminerva Med 52:9–25 pii:R41102476PubMed

60.

Zhu H, Tannous P, Johnstone JL, Kong Y, Shelton JM, Richardson JA, Le V, Levine B, Rothermel BA, Hill JA (2007) Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 117:1782–1793. doi:10.1172/JCI27523 PubMedCrossRef

61.

Zolk O, Schenke C, Sarikas A (2006) The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 70:410–421. doi:10.1016/j.cardiores.2005.12.021 PubMedCrossRef

Title: Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy
Publication date: 01-01-2012
Published in: Basic Research in Cardiology / Issue 1/2012
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-011-0235-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update

Reverse chamber remodelling following adrenergic-induced advanced cardiac dilatation and pump dysfunction

Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction

Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients

Erratum to: Conditional transgenic expression of TIR-domain-containing adaptor-inducing interferon-β (TRIF) in the adult mouse heart is protective in acute viral myocarditis

Regulatory T cells ameliorate cardiac remodeling after myocardial infarction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page